Ramón
García Sanz
Profesor Titular de Universidad
Pierre and Marie Curie University
París, FranciaPublicacions en col·laboració amb investigadors/es de Pierre and Marie Curie University (10)
2022
-
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433
-
High frequency of central nervous system involvement in transformed Waldenstrom € macroglobulinemia
Blood Advances
-
IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385
-
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
2021
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
2020
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
-
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018
2009
-
International prognostic scoring system for Waldenström macroglobulinemia
Blood, Vol. 113, Núm. 18, pp. 4163-4170